These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12962750)

  • 1. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions.
    Ruiz JC; Campistol JM; Mota A; Prats D; Gutiérrez JA; Castro A; García J; Morales JM; Grynió JM; Gómez JM; Arias M
    Transplant Proc; 2003 Aug; 35(5):1669-70. PubMed ID: 12962750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions.
    Ruiz JC; Campistol JM; Grinyó JM; Mota A; Prats D; Gutiérrez JA; Henriques AC; Pinto JR; García J; Morales JM; Gómez JM; Arias M
    Transplantation; 2004 Nov; 78(9):1312-8. PubMed ID: 15548969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus attenuates the rate of progression of early chronic allograft nephropathy.
    Sumethkul V; Changsirikulchai S; Lothuvachai T; Chalermsanyakorn P
    Transplant Proc; 2006 Dec; 38(10):3470-2. PubMed ID: 17175307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early cyclosporine a withdrawal in kidney transplant recipients under a sirolimus-based immunosuppressive regimen: pathological study of graft biopsies at 1-year posttransplant.
    Ruiz JC; Campistol JM; Mota A; Prats D; Gutiérrez A; Castro A; Pinto JR; García J; Morales JM; Grinyo JM; Arias M
    Transplant Proc; 2002 Feb; 34(1):92-3. PubMed ID: 11959199
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria.
    Ruiz JC; Campistol JM; Sanchez-Fructuoso A; Mota A; Grinyo JM; Paul J; Castro-Henriques A; Reimao-Pinto J; Garcia J; Morales JM; Granados E; Arias M
    Transplant Proc; 2007 Sep; 39(7):2151-2. PubMed ID: 17889121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years.
    Mota A; Arias M; Taskinen EI; Paavonen T; Brault Y; Legendre C; Claesson K; Castagneto M; Campistol JM; Hutchison B; Burke JT; Yilmaz S; Häyry P; Neylan JF;
    Am J Transplant; 2004 Jun; 4(6):953-61. PubMed ID: 15147430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
    Johnson RW; Kreis H; Oberbauer R; Brattström C; Claesson K; Eris J
    Transplantation; 2001 Sep; 72(5):777-86. PubMed ID: 11571437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid.
    Citterio F; Sparacino V; Altieri P; Rigotti P; Calabrese S; Poli M; Vinti V; Segoloni GP
    Transplant Proc; 2005 Mar; 37(2):827-9. PubMed ID: 15848545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo sirolimus-based regimen in Thai renal transplant recipients.
    Townamchai N; Avihingsanon Y; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
    Transplant Proc; 2008 Sep; 40(7):2206-8. PubMed ID: 18790193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy.
    Liu M; Zhang W; Gu M; Yin C; Zhang WY; Lv Q; Xu D
    Transplant Proc; 2007 Jun; 39(5):1410-5. PubMed ID: 17580150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus.
    Tedesco-Silva H; Garcia VD; Contieri FL; De Boni Monteiro de Carvalho D; Noronha IL; Gonçalves RT; de Paula FJ; Abbud-Filho M; Manfro RC; David-Neto E; Alfieri F; Ikehara E; Jiang Q; Tai SS; Medina-Pestana JO
    Transplant Proc; 2010 Jun; 42(5):1659-66. PubMed ID: 20620495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus improves the two-year outcome of renal allografts in African-American patients.
    Podder H; Podbielski J; Hussein I; Katz S; Van Buren C; Kahan BD
    Transpl Int; 2001 Jun; 14(3):135-42. PubMed ID: 11499902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.
    Stallone G; Di Paolo S; Schena A; Infante B; Grandaliano G; Battaglia M; Gesualdo L; Schena FP
    Transplantation; 2003 Apr; 75(7):998-1003. PubMed ID: 12698087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to sirolimus allows preservation of renal function in kidney and kidney-pancreas allograft recipients.
    Laham G; Sleiman S; Soler Pujol G; Diaz C; Dávalos M; Vilches A
    Transplant Proc; 2010; 42(1):309-13. PubMed ID: 20172338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
    Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
    Boratyńska M; Banasik M; Watorek E; Falkiewicz K; Patrzałek D; Szyber P; Klinger M
    Transplant Proc; 2006; 38(1):101-4. PubMed ID: 16504675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.